HPV Testing and PAP Test Market Report by Test Type (HPV Test, Pap Test, Co-testing), Product (Instruments, Consumables, Services), Application (Cervical Cancer Screening, Vaginal Cancer Screening), End User (Hospitals and Clinics, Laboratories, Diagnostic Centers, and Others), and Region 2025-2033

HPV Testing and PAP Test Market Report by Test Type (HPV Test, Pap Test, Co-testing), Product (Instruments, Consumables, Services), Application (Cervical Cancer Screening, Vaginal Cancer Screening), End User (Hospitals and Clinics, Laboratories, Diagnostic Centers, and Others), and Region 2025-2033

Report Format: PDF+Excel | Report ID: SR112025A5889

Market Overview:

The global HPV testing and PAP test market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 7.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033. 

Report Attribute 
Key Statistics
Base Year
2024
Forecast Years
2025-2033
Historical Years
2019-2024
Market Size in 2024
USD 4.4 Billion
Market Forecast in 2033
USD 7.0 Billion
Market Growth Rate (2025-2033) 4.96%


Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices. 

HPV Testing and PAP Test Market Trends:

The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth. In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor. This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global HPV testing and PAP test market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on test type, product, application and end user.

Breakup by Test Type:

  • HPV Test
  • Pap Test
  • Co-testing
     

Breakup by Product:

  • Instruments
  • Consumables
  • Services
     

Breakup by Application:

  • Cervical Cancer Screening
  • Vaginal Cancer Screening
     

Breakup by End User:

  • Hospitals and Clinics
  • Laboratories
  • Diagnostic Centers
  • Others
     

Breakup by Region:

HPV Testing and PAP Test Market By Region

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa
     

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.

Report Coverage:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units  Billion USD
Segment Coverage Test Type, Product, Application, End User, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)

Key Questions Answered in This Report

The global HPV testing and PAP test market was valued at USD 4.4 Billion in 2024.

We expect the global HPV testing and PAP test market to exhibit a CAGR of 4.96% during 2025-2033.

The increasing prevalence of cervical cancer, along with the introduction of machine-assisted, plasma- and cell-free Deoxyribonucleic Acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at an early phase, is primarily driving the global HPV testing and PAP test market.

The sudden outbreak of the COVID-19 pandemic has led to the continuous clinical trials, developments, and product launches, such as the easy-to-use home HPV screening test, as it allows to combat the spread of the coronavirus infection upon hospital visits and interaction with medical equipment.

Based on the test type, the global HPV testing and PAP test market has been bifurcated into HPV test, pap test, and co-testing. Among these, pap test currently holds the majority of the total market share.

Based on the product, the global HPV testing and PAP test market can be segmented into instruments, consumables, and services. Currently, consumables exhibit a clear dominance in the market.

Based on the application, the global HPV testing and PAP test market has been divided into cervical cancer screening and vaginal cancer screening, where cervical cancer screening currently accounts for the largest market share.

Based on the end user, the global HPV testing and PAP test market can be segregated into hospitals and clinics, laboratories, diagnostic centers, and others. Currently, hospitals and clinics exhibit a clear dominance in the market.

On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.

Some of the major players in the global HPV testing and PAP test market include Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc., and Thermo Fisher Scientific Inc.

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
HPV Testing and PAP Test Market Report by Test Type (HPV Test, Pap Test, Co-testing), Product (Instruments, Consumables, Services), Application (Cervical Cancer Screening, Vaginal Cancer Screening), End User (Hospitals and Clinics, Laboratories, Diagnostic Centers, and Others), and Region 2025-2033
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials